Immunogenicity and efficacy of recombinant subunit SARS-CoV-2 vaccine candidate in the Syrian hamster model
Issued Date
2023-03-01
Resource Type
eISSN
2215017X
Scopus ID
2-s2.0-85144032360
Journal Title
Biotechnology Reports
Volume
37
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biotechnology Reports Vol.37 (2023)
Suggested Citation
Shanmugaraj B., Khorattanakulchai N., Paungpin W., Akkhawattanangkul Y., Manopwisedjaroen S., Thitithanyanont A., Phoolcharoen W. Immunogenicity and efficacy of recombinant subunit SARS-CoV-2 vaccine candidate in the Syrian hamster model. Biotechnology Reports Vol.37 (2023). doi:10.1016/j.btre.2022.e00779 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81646
Title
Immunogenicity and efficacy of recombinant subunit SARS-CoV-2 vaccine candidate in the Syrian hamster model
Author's Affiliation
Other Contributor(s)
Abstract
SARS-CoV-2 causes devastating impact on the human population and has become a major public health concern. The frequent emergence of SARS-CoV-2 variants of concern urges the development of safe and efficacious vaccine against SARS-CoV-2 variants. We developed a candidate vaccine Baiya SARS-CoV-2 Vax 1, based on SARS-CoV-2 receptor-binding domain (RBD) by fusing with the Fc region of human IgG. The RBD-Fc fusion was produced in Nicotiana benthamiana. Previously, we reported that this plant-produced vaccine is effective in inducing immune response in both mice and non-human primates. Here, the efficacy of our vaccine candidate was tested in Syrian hamster challenge model. Hamsters immunized with two intramuscular doses of Baiya SARS-CoV-2 Vax 1 induced neutralizing antibodies against SARS-CoV-2 and protected from SARS-CoV-2 challenge with reduced viral load in the lungs. These preliminary results demonstrate the ability of plant-produced subunit vaccine Baiya SARS-CoV-2 Vax 1 to provide protection against SARS-CoV-2 infection in hamsters.